Efficacy, Safety and Patient-Reported Outcomes with Preservative-Free (PF) Tafluprost or PF-Dorzolamide/Timolol Compared with Preserved Latanoprost: A Prospective Multicenter Study in Korean Glaucoma Patients with Ocular Surface Disease
- 문서 유형
- 연구출판물 · 학술지 논문
- 등재
- SCIEScopus
- 저널 순위
- JCR Q1Scopus Q2
- 저널
- PHARMACEUTICALS15(2) · 2022
- 피인용
- Web of Science 6Scopus 8
- FWCI (Scopus)
- 0.68
- JCR IF
- JCR 2021 5.215
- ISSN
- 1424-8247
저자
- Park, Sang-Woo제1저자Chonnam Natl Univ Hosp, Gwangju 61469, South Korea
- 이지웅Pusan Natl Univ Hosp, Busan 49241, South Korea
- Kook, Michael S.교신저자Univ Ulsan, Asan Med Ctr, Dept Ophthalmol, Coll Med, Seoul 05505, South Korea
초록
© 2022 by the authors. Licensee MDPI, Basel, Switzerland.To compare the efficacy, patient-reported satisfaction, and safety of preservative-free (PF)-tafluprost, PF-dorzolamide/timolol and preservative-containing (P)-latanoprost in Korean glaucoma patients with ocular surface disease (OSD). In a multicenter, prospective, interventional, non-randomized, controlled 12-week trial, 107 eligible patients received PF-tafluprost (n = 37), PF-dor-zolamide/timolol (n = 34), or P-latanoprost eye drops (n = 36). Outcomes included changes from baseline in OSD Index (OSDI) scores (primary endpoint), intraocular pressure (IOP), and patient-reported treatment satisfaction, and safety at 12 weeks. At 12 weeks, the mean total OSDI and sub-domain (dry eye symptoms, visual-related function, environmental triggers) scores significantly improved from baseline with PF-tafluprost and PF-dorzolamide/timolol, but not with P-latano-prost. Significantly more PF-tafluprost than P-latanoprost recipients reported ‘highly improved/im-proved’ satisfaction (no significant difference between PF-dorzolamide/timolol and P-latanoprost). IOP changes were comparable among all three treatment groups. No new safety concerns were ob-served. PF-tafluprost and PF-dorzolamide/timolol showed statistically and clinically significant re-ductions in OSDI compared with P-latanoprost in Korean glaucoma patients with OSD.
키워드
Dorzolamide/timololGlaucomaOcular surface diseaseP-latanoprostPreservative-freeTafluprostQUALITY-OF-LIFEVISUAL-FIELD LOSSDRY EYE DISEASEBENZALKONIUM CHLORIDELONGITUDINAL CHANGESPREVALENCEMEDICATIONSIMPACTSYMPTOMSTOXICITY
식별자
- Scopus EID
- 2-s2.0-85124537851
- WoS UID
- 000826768400002



로그인
연구물 목록으로